Galux
Address: 3-6th floor, 1837, Nambu Sunhwan-ro,, Gwanak-gu,, Seoul,About Us
Galux was established in 2020 with the incorporation of molecular design technology that has been honed over a period of 15 years at Seoul National University. This technology leverages the integration of AI, physics, and chemistry to produce exceptional results, as evidenced by its performance in the CASP and CAPRI competitions. Built on a foundation of advanced research and development capabilities, Galux is currently developing a drug design platform that incorporates protein structure prediction, protein-protein interaction prediction, and protein-ligand interaction prediction technologies. The company is also focused on identifying and developing novel therapeutics for incurable and rare diseases through its AI-based drug design platform
Sectors
- Software Services
- Collaborations & Partnerships- R&D
- Collaborations & Partnerships-Licensing
- Collaborations & Partnerships-Services
Categories
- Drug Discovery Services
- Platform Technology-Drug Discovery
- Software
- Drug Development Services
- Artificial Intelligence
- Proteins
- Software-AI
- Software-3D
- Drug Design
News
Galux Announces Research Agreement with Boehringer Ingelheim to Advance AI-Driven Protein Design
Galux announced that it has entered into a research agreement with Boehringer Ingelheim to jointly explore the application of artificial intelligence in precision protein design for therapeutic development. The goal is to evaluate how AI can be leveraged to design purpose-specific protein molecules that meet precise scientific and translational needs, where conventional approaches face limitations.
“Through this agreement, we aim to explore how AI protein design can address highly specific scientific and translational needs — challenges that often require precise and tailored molecular solutions,” said Chaok Seok, CEO of Galux. “It’s about demonstrating that AI can move beyond prediction to purposeful molecular design, creating proteins that meet clearly defined research and therapeutic goals.”
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com